Peptide library / Immune & defense / Echinocandins
Echinocandins
A class of cyclic lipopeptide antifungals and first-line treatment for invasive Candida infections.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Invasive candidiasisFDA approved
- Aspergillosis when other drugs failFDA approved
How it is thought to work
Echinocandins block the enzyme that builds the fungal cell wall, which human cells do not have.
What the evidence shows
Trials and guidelines support them as first choice for candidemia. Rezafungin, approved in 2023, is given once a week.
Safety and unknowns
Generally well tolerated. Liver enzyme rises and infusion reactions can occur.
Regulatory status
FDA-approved: caspofungin in 2001, micafungin, anidulafungin and rezafungin later.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Immune & defense
Enfuvirtide
FDA-approvedA 36 amino acid injectable HIV drug, the first fusion inhibitor.
Glatiramer acetate
FDA-approvedA random mixture of four amino acids used in relapsing multiple sclerosis.
Daptomycin
FDA-approvedA cyclic lipopeptide antibiotic from soil bacteria for serious skin and bloodstream infections.
General information, not medical advice. Do not buy or inject unregulated peptides.